A digital view of the world illustrates how Astellas is a global company committed to serving patients worldwide.

News

Astellas is committed to providing timely and accurate information about our business, science and products. This section offers global resources for investors, journalists and media professionals. News and resources from our local affiliates can be viewed in the Local news section. If you are not an investor or journalist, click here.

Month Year

Apr 21, 2020

Astellas Announces Acquisition of Nanna

-Nanna’s unique screening platform has great potential to create novel programs, leading to maximization of mitochondria-related research

TOKYO and CAMBRIDGE (UK), April 21, 2020 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and Nanna Therapeutics Limited (CEO: David Williams, Ph.D., “Nanna”) today announced that Astellas has acquired Nanna, a biotech...

Read more
Apr 10, 2020

Astellas Announces Acceptance of XOSPATA® (gilteritinib) for Regulatory Review in China by the National Medical Products Administration

TOKYO, April 10, 2020 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) announced today a new drug application (NDA) for the oral once-daily therapy XOSPATA® (gilteritinib), for the treatment of adult patients...

Read more
Apr 6, 2020

Three Astellas Research and Production Facilities in Japan Adopt Aqua Premium

- Switching to greenhouse gas emission-free hydroelectric power -

TOKYO, April 6, 2020 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced that three of its research and production facilities in Japan will be changing their electricity supply plan to the Aqua Premium1 plan...

Read more
Apr 6, 2020

Astellas and BANDAI NAMCO Entertainment Enter into Agreement to Co-Develop and Co-Commercialize Smartphone Exercise Support Application

- Medical and health research using application for smartphone and other devices is conducted, and development of application for pilot marketing will begin in FY2020 -

TOKYO , April 6, 2020 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and BANDAI NAMCO Entertainment Inc. (President and CEO: Yasuo Miyakawa, “BANDAI NAMCO Entertainment”) today announced that the two...

Read more
Mar 23, 2020

CytomX Therapeutics and Astellas Announce Strategic Collaboration to Develop Probody® T-Cell Engaging Bispecific Therapies for Treatment of Cancer

- Collaboration to Utilize CytomX’s Novel Probody® Technology Platform for CD3 Bispecific Targets -

SOUTH SAN FRANCISCO, CA and Tokyo, March 23, 2020 - CytomX Therapeutics, Inc. (NASDAQ: CTMX, President, Chief Executive Officer and Chairman: Sean McCarthy, D. Phil. “CytomX”) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa...

Read more
Mar 18, 2020

Gifu University and Astellas establish a Research Course on Phage Biologics, aimed at creating new treatments for bacterial infections

TOKYO , March 18, 2020 - Gifu University (President: Hisataka Moriwaki M.D., Ph.D.) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced that the parties have established, inside Gifu University Graduate School...

Read more
Feb 27, 2020

Notice Regarding the Performance-linked Stock Compensation Scheme and Performance-linked Stock Delivery Scheme for the Domestic and Global Astellas Group Executives

TOKYO, February 27, 2020 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “the Company”) today announced that at the meeting of the Board of Directors held today...

Read more
Feb 19, 2020

Astellas and Seattle Genetics Receive FDA Breakthrough Therapy Designation for PADCEV™ (enfortumab vedotin-ejfv) in Combination with Pembrolizumab in First-Line Advanced Bladder Cancer

- Breakthrough Therapy Designation Based on Initial Results from Phase 1b/2 EV-103 Clinical Trial -

TOKYO and BOTHELL, Wash., February 19, 2020 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and Seattle Genetics, Inc. (Nasdaq:SGEN) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough...

Read more
Feb 11, 2020

XTANDI® (enzalutamide) Demonstrates Significant Improvement in Overall Survival in Phase 3 PROSPER Trial of Patients with nmCRPC

TOKYO and NEW YORK, February 11, 2020 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and Pfizer Inc. (NYSE: PFE) announced today results of the final overall survival (OS) analysis from the Phase 3 PROSPER trial, which...

Read more
Feb 10, 2020

Seattle Genetics and Astellas Announce Updated Results from Phase 1b/2 Trial of PADCEV™ (enfortumab vedotin-ejfv) in Combination with Immune Therapy Pembrolizumab as Investigational First-Line Treatment for Advanced Bladder Cancer

- After Median Follow-Up of 11.5 Months, 73 Percent of Patients Had Confirmed Tumor Response with Majority of Responses Still Ongoing; No New Safety Signals Observed for the Combination -

BOTHELL, Wash. and TOKYO, February 10, 2020 – Seattle Genetics, Inc. (Nasdaq:SGEN) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced updated results from the phase 1b/2 clinical trial EV-103 in previously...

Read more
Feb 5, 2020

Astellas Announces Management Structure

TOKYO, February 5, 2020 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas” ) today announced the following Executive Comittee Standing Members effective...

Read more
Feb 4, 2020

Astellas Announces Completion of Acquisition of Own Shares, and Cancellation of Treasury Stock

TOKYO, February 4, 2020 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “the Company” ) announced the status and the completion of acquisition of its own shares based...

Read more
Jan 30, 2020

Astellas Submits Supplemental New Drug Application for Approval of Evrenzo® (roxadustat) for the Treatment of Anemia Associated with Chronic Kidney Disease in Non-Dialysis Dependent Patients in Japan

TOKYO and San Francisco, January 30, 2020 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and FibroGen, Inc. (Nasdaq: FGEN, CEO: Enrique Conterno, “FibroGen”) today announced the submission of a supplemental...

Read more
Jan 23, 2020

AMGEN ASTELLAS BIOPHARMA TO BECOME A WHOLLY OWNED AMGEN AFFILIATE ON APRIL 1, 2020 THE NEW COMPANY NAME WILL BE AMGEN K.K. THE HEADQUARTERS WILL RELOCATE TO TOKYO MIDTOWN

Co-Promotion of Repatha®, EVENITY®, and BLINCYTO® to Continue with Astellas

Amgen Inc. (Headquarters: Thousand Oaks, California, USA; Chairman and CEO: Robert A. Bradway; “Amgen”), Astellas Pharma Inc. (Headquarters: Tokyo; President and CEO: Kenji Yasukawa, PhD., “Astellas”), and Amgen Astellas BioPharma K.K...

Read more
Jan 17, 2020

Astellas Announces Construction of New Manufacturing Facility for Active Pharmaceutical Ingredient of Prograf® in Toyama Technology Center

TOKYO, January 17, 2020 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced that the Third Fermentation Building (provisional name) will be constructed as a new manufacturing facility for active pharmaceutical ingredient...

Read more
Jan 15, 2020

Astellas Completes Acquisition of Audentes Therapeutics

- Combined company positioned to become a global leader in AAV-based genetic medicines, with Audentes to operate as a wholly-owned subsidiary and Center of Excellence for Astellas’ newly created Genetic Regulation Primary Focus

TOKYO and San Francisco, January 15, 2020 - Astellas Pharma Inc. (TSE: 4503, President and Chief Executive Officer: Kenji Yasukawa, Ph.D., “Astellas”) today announced that it has successfully completed the previously announced acquisition of Audentes Therapeutics...

Read more
Jan 13, 2020

Astellas and Adaptimmune Enter into Agreement to Co-Develop and Co-Commercialize Stem-Cell Derived Allogeneic CAR-T and TCR T-Cell Therapies

- Agreement covers the co-development and co-commercialization of up to three T-cell therapies -

TOKYO and PHILADELPHIA, PA, OXFORDSHIRE, United Kingdom, January 13, 2020 (GLOBE NEWSWIRE) -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas"), through its wholly-owned subsidiary Universal Cells, Inc. and Adaptimmune...

Read more
Jan 6, 2020

Astellas Announces Status of Acquisition of Own Shares

TOKYO, January 6, 2020 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D. “the Company”) announced the status of acquisition of its own shares as stated below...

Read more
Dec 27, 2019

Astellas Strengthens Immuno-oncology Pipeline with Acquisition of Xyphos Biosciences, Inc.

Acquisition adds talent and proprietary therapeutic platform to accelerate next-generation cancer immunotherapy

TOKYO and SOUTH SAN FRANCISCO, Calif. - December 26, 2019 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and Xyphos Biosciences, Inc. (CEO: James...

Read more
Dec 21, 2019

Astellas Announces Production Subsidiary Astellas Pharma Tech Concludes Share Transfer Agreement with CMIC CMO for Succession of Nishine Plant Business

TOKYO, December 21, 2018 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas” ) today announced that Astellas Pharma Tech Co., Ltd. (“Astellas Pharma...

Read more
Dec 17, 2019

XTANDI® (enzalutamide) Approved by U.S. FDA for the Treatment of Metastatic Castration-Sensitive Prostate Cancer

NEW YORK and TOKYO, December 16, 2019 – Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) announced today that the U.S. Food...

Read more
Dec 16, 2019

Astellas Commences Tender Offer to Acquire All Outstanding Shares of Audentes

TOKYO, December 16, 2019 - Astellas Pharma Inc. (TSE:4503, Headquarters: Tokyo, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced that it has commenced, through its...

Read more
Dec 3, 2019

Astellas Enters into Definitive Agreement to Acquire Audentes Therapeutics

- Complementary capabilities and resources of the two organizations create an industry-leading gene therapy company

TOKYO and SAN FRANCISCO, December 2, 2019 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and Audentes Therapeutics, Inc. (NASDAQ: BOLD, Chairman and...

Read more
Dec 3, 2019

ACQUISITION OF AUDENTES Establishing a leading position in gene therapy

Read more
Dec 3, 2019

Seattle Genetics and Astellas Announce Clinical Trial Collaboration with Merck to Evaluate Enfortumab Vedotin in Combination with KEYTRUDA® (pembrolizumab) in Patients with Metastatic Urothelial Cancer

- Companies to Initiate Phase 3 Trial to Support Global Registrations -

BOTHELL, Wash., and TOKYO, December 2, 2019 – Seattle Genetics, Inc. (Nasdaq:SGEN) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”), today announced...

Read more
Dec 3, 2019

Astellas Presents New Data on XOSPATA® (gilteritinib) in FLT3 Mutation-Positive Relapsed/Refractory Acute Myeloid Leukemia at the 2019 American Society of Hematology Annual Meeting

Emerging mutations in patients with treatment resistance, from Phase 3 ADMIRAL study, will be focus of oral presentation

TOKYO, Dec. 3, 2019 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced the presentation of new data in acute myeloid leukemia (AML) at...

Read more
Dec 2, 2019

Astellas Announces Status of Acquisition of Own Shares

Read more
Nov 26, 2019

Astellas Announces the Approval of XTANDI® (enzalutamide) by the China National Medical Products Administration (NMPA) Approval based on Asian PREVAIL study of men with metastatic castration-resistant prostate cancer

TOKYO, November 26, 2019 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced that the China National Medical Products Administration...

Read more
Nov 21, 2019

Astellas and Welldoc Enter into Strategic Alliance for Digital Therapeutics - Develop and commercialize digital health solutions globally for multiple therapeutic areas, including in Japan for diabetes patients -

TOKYO and Columbia, Maryland, November 20, 2019 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas” ) and Welldoc, Inc. (President, CEO: Kevin McRaith,...

Read more
Nov 20, 2019

Launch of Evrenzo® (roxadustat) Tablets in Japan for the Treatment of Renal Anemia in Patients on Dialysis - First-in-Class Orally Administered HIF-PH Inhibitor -

TOKYO, November 20, 2019 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas” ) today announced launch of Evrenzo® Tablet 20mg, 50mg and 100mg (generic...

Read more
Oct 31, 2019

Astellas Announces Acquisition of Own Shares and Cancellation of Treasury Stock

(Acquisition of own shares pursuant to the provision of its Articles of Incorporation in accordance with Article 459, paragraph 1 of the Companies Act and cancellation of treasury stock pursuant to the provisions of Article 178 of the Companies Act)

Tokyo, October 31, 2019 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D.) today announced that at the meeting of the Board of Directors held today, a resolution was...

Read more
Oct 31, 2019

PANDION AND ASTELLAS ANNOUNCE COLLABORATION TO DELIVER PANCREAS-TARGETED IMMUNOMODULATORS

Exclusive Collaboration Utilizes Pandion’s Platform to Discover Novel Tissue-Specific Immunomodulators for Type 1 Diabetes and Other Autoimmune Diseases of the Pancreas

Cambridge, MA, and Tokyo, October 31, 2019 - Pandion Therapeutics, Inc. (“Pandion”), and Astellas Pharma Inc. (TSE: 4503, "Astellas") announced today the signing of a License and Collaboration...

Read more
Oct 31, 2019

New England Journal of Medicine Publishes Results from Astellas’ Phase 3 ADMIRAL Trial of XOSPATA® (gilteritinib) in Adult Patients with FLT3 Mutation-Positive Relapsed/Refractory Acute Myeloid Leukemia1

- Results were published online and in the October 31 print edition of the Journal -

TOKYO, October 31, 2019 - The New England Journal of Medicine published detailed results from the Phase 3 ADMIRAL trial, which found that Astellas Pharma Inc.’s (TSE: 4503, President and CEO:...

Read more
Oct 28, 2019

U.S. FDA Grants Fast Track Designation to Astellas for the Development of ASP1128 for Patients at Risk for Acute Kidney Injury

TOKYO, October 28, 2019 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced that the U.S. Food and Drug Administration (FDA) has granted...

Read more
Oct 25, 2019

European Commission Approves Astellas’ XOSPATA™ (gilteritinib) as a Monotherapy for Patients with Relapsed or Refractory Acute Myeloid Leukemia with a FLT3 Mutation

Approval follows accelerated assessment, orphan designation by European Medicines Agency

TOKYO, Oct. 25, 2019 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) announced today that the European Commission (EC) has approved the oral...

Read more
Oct 24, 2019

Astellas Announces Personnel Changes

Astellas Announces Personnel Changes

Read more
Oct 18, 2019

Annual Report 2019 is now available.

To enable deeper stakeholder understanding of Astellas' efforts to continue to create value for sustainable growth, we have published the annual report as an integrated report. In order to provide...

Read more
Oct 15, 2019

Astellas Transfers Three Products in Asia Region to Daiichi Sankyo

TOKYO, October 15, 2019 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas” ) today announced that subsidiaries of Astellas will transfer their marketing...

Read more
Oct 2, 2019

Astellas Commits Nearly $13 Million to Fund Boston-area Start-Up Innovation in Cell and Gene Therapy - Financial support for LabCentral Incubators builds on Astellas’ $1 Billion+ investment in Boston’s Life Science Community -

TOKYO, October 1 2019 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced it will invest nearly $13 million into two innovation incubators...

Read more
Sep 30, 2019

Seattle Genetics and Astellas Announce Results from Phase 1 Trial of Investigational Agent Enfortumab Vedotin in Combination with Immune Therapy Pembrolizumab as First-Line Treatment for Advanced Bladder Cancer

- Study Met Outcomes for Safety and 71 Percent of Patients with Locally Advanced or Metastatic Urothelial (Bladder) Cancer Had a Confirmed Response -

TOKYO and BOTHELL, Wash., September 28, 2019– Seattle Genetics, Inc. (Nasdaq:SGEN) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced...

Read more
Sep 24, 2019

Astellas Receives Positive CHMP Opinion for XOSPATA® (gilteritinib) as a Monotherapy for Patients with Relapsed or Refractory Acute Myeloid Leukemia with a FLT3 Mutation

If approved by the European Commission, gilteritinib would represent one of the few advances in Europe for AML over the past 40 years1

TOKYO, Sept. 20, 2019 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) announced today that the Committee for Medicinal Products for Human Use (CHMP)...

Read more
Sep 20, 2019

Evrenzo® (roxadustat) Tablets Approved in Japan for the Treatment of Anemia Associated with Chronic Kidney Disease in Dialysis Patients

TOKYO and San Francisco, September 20, 2019- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and FibroGen, Inc. (Nasdaq: FGEN, Interim CEO: James A...

Read more
Sep 17, 2019

Seattle Genetics and Astellas Announce US FDA Grants Priority Review for Enfortumab Vedotin Biologics License Application in Locally Advanced or Metastatic Urothelial Cancer

- Food & Drug Administration Sets Prescription Drug User Fee Action Date for March 15, 2020 -

BOTHELL, Wash. and TOKYO, September 16, 2019 – Seattle Genetics, Inc. (Nasdaq:SGEN) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced...

Read more
Sep 13, 2019

Astellas and iota Biosciences Enter into Collaborative Research and Development Agreement -Companies to explore new biosensing and treatment measures using ultra-small implantable medical devices-

TOKYO and Berkeley, CA., September 13, 2019 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas” ) and Iota Biosciences, Inc. (Co-founders and Co-CEOs:...

Read more
Sep 2, 2019

RIKEN and Astellas Enter into Worldwide Exclusive Licensing Agreement for Artificial Adjuvant Vector Cell Technology in Oncology

Saitama and Tokyo, September 2, 2019 - RIKEN (President: Hiroshi Matsumoto, Ph.D.) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) announced today...

Read more
Aug 22, 2019

U.S. FDA Grants XTANDI® (enzalutamide) Application Priority Review for the Treatment of Men with Metastatic Hormone-Sensitive Prostate Cancer

XTANDI Supplemental New Drug Application (sNDA) Seeks to Add an Indication for Men with Prostate Cancer that Has Spread but Is Sensitive to Hormone Therapy

TOKYO and NEW YORK, August 21, 2019 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") and Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and...

Read more
Aug 9, 2019

Yokohama City University, Tokyo University of the Arts and Astellas Launched Health Mock Lab. to Create New Digital Healthcare Solutions Using Gamification

TOKYO, August 9, 2019 - Yokohama City University (Kanagawa, Chairperson of the Board of Trustees and CEO: Yoshiyuki Futami, “YCU”) , Tokyo University of the Arts (Tokyo, President: Kazuki...

Read more
Aug 6, 2019

Astellas Initiates Phase 3 Clinical Trials for Fezolinetant in Postmenopausal Women with Vasomotor Symptoms

TOKYO, August 6, 2019 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced dosing of the first patient in the SKYLIGHT 1™ Phase 3 pivotal...

Read more
Jul 30, 2019

Astellas Submits Supplemental New Drug Application for Approval of Additional Indication of XTANDI® for the Treatment of Men with Metastatic Hormone-Sensitive Prostate Cancer in Japan

TOKYO, July 30, 2019 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas” ) today announced that it has submitted a supplemental new drug application for the...

Read more
Jul 24, 2019

Astellas Announces Acceptance by the European Medicines Agency of a Variation Application for Regulatory Review for Use of XTANDITM (enzalutamide) in metastatic Hormone-Sensitive Prostate Cancer

TOKYO AND CHERTSEY, July 24 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) announced the acceptance by the European Medicines Agency (EMA) of a Type...

Read more

Show per page

Discover more

Media contacts

Return to media homepage

Subscribe to news alerts

Choose Language

News